You are here

Online Treatment of Subretinal Neovascular Membranes from Laser Eye Injury

Award Information
Agency: Department of Defense
Branch: Army
Contract: W81XWH-06-C-0397
Agency Tracking Number: A064-030-0270
Amount: $749,934.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: A06-T030
Solicitation Number: N/A
Timeline
Solicitation Year: 2006
Award Year: 2007
Award Start Date (Proposal Award Date): 2007-09-11
Award End Date (Contract End Date): 2008-09-09
Small Business Information
20 New England Business Center
Andover, MA 01810
United States
DUNS: 073800062
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Daniel Hammer
 Group Leader, Biomedical Imaging
 (978) 689-0003
 hammer@psicorp.com
Business Contact
 B. Green
Title: President, PSI R&D Operations
Phone: (978) 689-0003
Email: green@psicorp.com
Research Institution
 BOSTON UNIV.
 Jane Kinsel
 
School of Medicine 1 Sherborn Street
Boston, MA 2215
United States

 (617) 638-4600
 Nonprofit College or University
Abstract

Subretinal neovascular membranes are a deleterious complication of laser eye injury and retinal diseases such as age-related macular degeneration (AMD), choroiditis, and myopic retinopathy. Photodynamic therapy (PDT) and anti-vascular endothelial growth factor (VEGF) drugs are approved treatment methods. PDT acts by selective dye accumulation, activation by laser light, and disruption and clotting of the new leaky vessels. However, PDT surgery is currently not image-guided, nor does it proceed in an efficient or automated manner. This may contribute to the high rate of re-treatment. Physical Sciences Inc. and Boston University Medical Center have successfully completed a Phase I STTR program to initiate the development of an on-line, automated, image-guided PDT treatment system. The system is built around core technologies of line scanning laser ophthalmoscopy and retinal tracking. In addition to those components, the compact multifunctional optical platform to be constructed in Phase II will include both fluorescein and ICG angiography as well as precise delivery of a PDT treatment laser beam. The system will be tested in a limited number of human subjects with AMD. At the end of the program the system will be delivered to the U.S. Army Medical Research Detachment at Brooks City Base San Antonio, TX.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government